Camber Capital Management LP Incyte Corp Transaction History

Camber Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $29.8 Million - $37.3 Million	-450,000 Reduced 37.5%	750,000 $50 Million
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $9.93 Million - $12.5 Million	-150,000 Reduced 11.11%	1,200,000 $91.2 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $29.7 Million - $35.9 Million	450,000 Added 50.0%	1,350,000 $107 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $57 Million - $66.7 Million	900,000 New	900,000 $66.1 Million
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $39.9 Million - $43.8 Million	-500,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $38 Million - $50.3 Million	500,000 New	500,000 $40.6 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $26.7 Million - $39.3 Million	-360,457 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$63.18 - $85.97 $22.8 Million - $31 Million	360,457 New	360,457 $26.4 Million

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.